Dicerna Pharmaceuticals (DRNA) PT Lowered to $22 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Stifel Reiterates Buy Rating on Dicerna Pharmaceuticals (DRNA)
March 12, 2019 6:48 AM EDTStifel analyst reiterated a Buy rating and $22.00 price target on Dicerna Pharmaceuticals (NASDAQ: DRNA)
For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.
Shares of Dicerna Pharmaceuticals closed at $11.74 yesterday.
... MoreDicerna Pharma (DRNA) Misses Q4 EPS by 7c, Revenues Miss
March 11, 2019 4:26 PM EDTDicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.54 million versus the consensus estimate of $7.78 million.
2018 was a year of tremendous achievement for Dicerna. During the year, we met each of our key strategic objectives, as we obtained strong proof-of-concept (POC) data for our lead... More
